Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?

Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text]

Detalles Bibliográficos
Autores principales: De Luca, Michele, Cossu, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Science & Society
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/
https://www.ncbi.nlm.nih.gov/pubmed/36592141
http://dx.doi.org/10.15252/embr.202256661
Descripción
Sumario:Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.[Image: see text]

Ejemplares similares